|Bid||0.680 x 900|
|Ask||0.816 x 1200|
|Day's Range||0.7900 - 0.8200|
|52 Week Range||0.6400 - 5.5000|
|Beta (3Y Monthly)||1.34|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.00|
CEO Jim Schutz and CFO Robert Miller Step DownFrederick (Bubba) Sandford Appointed as New CEO and Interim CFO and will Join the Board PETALUMA, Calif., Dec. 14, 2018 -- Sonoma.
If you own shares in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) then it's worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure Read More...
NEW YORK, Nov. 21, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Sonoma Pharmaceuticals, Inc. (SNOA) today announced the pricing of a “best efforts” public offering of units consisting of one share of common stock, together with one half of one warrant to purchase one share of common stock at an exercise price equal to $1.00 per whole share. The public offering price was $1.00 per unit. Certain investors, who would beneficially own, together with its affiliates and certain related parties, more than 4.99% of the outstanding common stock as a result of the public offering, can purchase series C convertible preferred stock convertible into shares of common stock, in lieu of purchasing common stock.
NEW YORK, NY / ACCESSWIRE / November 16, 2018 / Pharmaceutical companies Arena Pharmaceuticals and Sonoma Pharmaceuticals were in the green on Thursday. While Sonoma did not have any news to note, Arena Pharmaceuticals announced that it has entered into a lucrative licensing agreement with United Therapeutics. Arena Pharmaceuticals, Inc. shares were up 22.62% yesterday on around 4.7 million shares traded.
Sonoma Pharmaceuticals, Inc. (SNOA) today announced that financial results for its fiscal year 2019 second quarter, ended September 30, 2018, will be released after the U.S. markets close on November 8, 2018. The earnings release will be followed by a conference call at 1:30 p.m. PST on November 8, 2018, to discuss fiscal second quarter results. Individuals interested in participating in the conference call may do so by dialing 877-303-7607 for domestic callers or 973-638-3203 for international callers. Those interested in listening to the conference call live via the internet may do so at https://edge.media-server.com/m6/p/b5tvh3bj. A telephone replay will be available for seven days following the conclusion of the call by dialing 855-859-2056 for domestic callers, or 404-537-3406 for international callers, and entering conference code 3686329.
Sonoma Pharmaceuticals, Inc. (SNOA), today announced newly published results from a study into the use of the company’s proprietary Performance Stabilized HOClTM (hypochlorous acid) for the management of scars. Silicone-based products are currently recommended as the first-line option for preventing and treating excessive scarring after surgery or trauma.
A look at the shareholders of Sonoma Pharmaceuticals Inc (NASDAQ:SNOA) can tell us which group is most powerful. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, Read More...
NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA ) will be discussing their earnings results in their Q1 Earnings Call to be held on August 8, 2018 at 4:30:00 PM ...
While small-cap stocks, such as Sonoma Pharmaceuticals Inc (NASDAQ:SNOA) with its market cap of US$16.23m, are popular for their explosive growth, investors should also be aware of their balance sheetRead More...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 13) ABIOMED, Inc. (NASDAQ: ABMD ) AngioDynamics, Inc. (NASDAQ: ...
Sonoma Pharmaceuticals Inc (NASDAQ:SNOA) is a small-cap stock with a market capitalization of US$18.21M. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, theyRead More...